Novartis Investigative Site

Dippoldiswalde-Schmiedeberg 01744

0 studies enrolling now · 2 studies all time

What they study most

Moderate to Severe Chronic Plaque-Type Psoriasis, Moderate to Severe Plaque-type Psoriasis

Studies at this site

• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis — Completed
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — Completed